Petros Grivas MD, PhDAssociate Professor, Department of Medicine, Division of Oncology; Clinical Director, Genitourinary Cancers Program, University of Washington; Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
Dr. Grivas has published widely in peer-reviewed journals and has authored more than 50 articles and book chapters. He is a member of the International Bladder Cancer Network, the Bladder Cancer Advocacy Network, the American Society of Clinical Oncology, and the American Association for Cancer Research, among other professional organizations.
With a strong interest in designing and conducting clinical trials, Dr. Grivas’s professional interests also involve clinical and translational research on experimental therapeutics in genitourinary cancers via a molecular biology–based approach aiming to translate results into clinical trials.
Having received his medical degree and a PhD in medical oncology from the University of Patras School of Medicine in Greece, Dr. Grivas came to the US for his internal medicine residency at Drexel University College of Medicine/Hahnemann University Hospital in Philadelphia. He completed a fellowship in hematology/oncology at the University of Michigan in 2013, and took part in the GME Scholars Health Care Administration and Leadership Program at Michigan between 2012 and 2014.
Dr. Grivas has a consulting/advisory role with Merck & Co., Bristol- Myers Squibb, AstraZeneca, Clovis Oncology, EMD Serono, Seattle Genetics, Foundation Medicine, Driver Inc., QED Therapeutics, HERON, Janssen, Bayer, Genzyme, Mirati Therapeutics, Exelixis, Roche, GlaxoSmithKline, and Pfizer.
His instituion receives research funding from Clovis Oncology, Bavarian Nordic, Immunomedics, Bristol-Myers Squibb, Debiopharm Group, and Pfizer.
Recent Contributions to PracticeUpdate:
- Impact of Age and Performance Status on Outcomes With First-Line Pembrolizumab for Advanced Urothelial Carcinoma
- ASCO: Adjuvant Atezolizumab for High-Risk Muscle-Invasive Bladder Cancer
- ASCO: Maintenance Avelumab After First-Line Chemotherapy for Patients With Advanced Urothelial Carcinoma
- Next-Generation Sequencing in Advanced Urothelial Carcinoma
- Dr. Petros Grivas on Switching Jobs: Part 3
- Dr. Petros Grivas on Switching Jobs: Part 2
- Dr. Petros Grivas on Switching Jobs: Part 1
- Implications of Basket Trial Data for Urothelial Carcinoma
- Future Directions for PARP Inhibitors in Metastatic Urothelial Carcinoma
- Cost-Effectiveness of Pembrolizumab for Advanced Urothelial Carcinoma